ReviewBiotechnology letters2026
Plant-derived vaccines for veterinary disease management in ruminants and swine.
Review in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination remains one of the effective strategies to control infectious diseases, thereby preventing millions of deaths each year globally. Veterinary vaccines protects animal and public health, enabling efficient production of livestock, reduce antibiotic use and also prevent zoonotic spill over events. Traditional vaccines were developed using live-attenuated or inactivated pathogens. However, the advancements in the genetic engineering and recombinant protein production technologies have made possible the vaccine design and production of recombinant vaccine antigens or immunotherapeutic molecules for both human and veterinary use. Most of the commercially available recombinant therapeutic proteins are produced in mammalian system which limits their feasibility, particularly for veterinary applications due to their high production costs. Therefore, the development of low cost products using alternative production platforms is highly essential. The utilization of plant expression system for the recombinant vaccine production has increased in the recent years due to its advantages such as low production costs, scalability, safety, and the ability to express complex proteins. This review provides a comprehensive overview of the vaccine antigens produced in plant system with a particular focus on vaccines targeting infectious diseases in ruminants and swine.
Indexed as
Identifiers
41792499What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.